long intergenic non-protein coding RNA 1830Genealiases: []
Q-omics provides the consensus-scored LINC01830 profile across patient tissues and cancer cell-line models. LINC01830 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01830 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, LINC01830 RNA expression shows 7,871 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight SKCM, KIRP, and COAD as cancer lineages where LINC01830 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01830 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01830 survival associations across molecular data types. LINC01830 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01830 RNA expression–survival associations across cancer types. High LINC01830 expression shows unfavorable associations in SKCM, PAAD, LIHC, THCA and STAD, but favorable associations in LUSC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01830 RNA expression.
This table summarizes LINC01830 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01830. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01830 shows lower tumor expression in KIRP and KIRC. The KIRP box plot shows higher LINC01830 RNA expression in normal versus tumor tissue (log2 FC = −0.010, t-test p = .039).
This table shows molecular features associated with LINC01830 in patient tissues and cancer cell lines. In patient samples, LINC01830 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
